123 related articles for article (PubMed ID: 26045011)
1. Eribulin Shows Promise in Advanced Sarcoma.
Cancer Discov; 2015 Jul; 5(7):OF4. PubMed ID: 26045011
[No Abstract] [Full Text] [Related]
2. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.
Schöffski P; Chawla S; Maki RG; Italiano A; Gelderblom H; Choy E; Grignani G; Camargo V; Bauer S; Rha SY; Blay JY; Hohenberger P; D'Adamo D; Guo M; Chmielowski B; Le Cesne A; Demetri GD; Patel SR
Lancet; 2016 Apr; 387(10028):1629-37. PubMed ID: 26874885
[TBL] [Abstract][Full Text] [Related]
3. Eribulin in soft-tissue sarcoma.
Young RJ; Woll PJ
Lancet; 2016 Apr; 387(10028):1594-6. PubMed ID: 26874886
[No Abstract] [Full Text] [Related]
4. Sarcoma: Eribulin--a welcomed advance.
Romero D
Nat Rev Clin Oncol; 2016 Apr; 13(4):204. PubMed ID: 26925959
[No Abstract] [Full Text] [Related]
5. Eribulin: an effective therapeutic option in liposarcoma.
Das M
Lancet Oncol; 2017 Oct; 18(10):e569. PubMed ID: 28890295
[No Abstract] [Full Text] [Related]
6. Molecular Biomarkers of Response to Eribulin in Patients with Leiomyosarcoma.
Wozniak A; Boeckx B; Modave E; Weaver A; Lambrechts D; Littlefield BA; Schöffski P
Clin Cancer Res; 2021 Jun; 27(11):3106-3115. PubMed ID: 33795257
[TBL] [Abstract][Full Text] [Related]
7. Eribulin in advanced liposarcoma and leiomyosarcoma.
Setola E; Noujaim J; Benson C; Chawla S; Palmerini E; Jones RL
Expert Rev Anticancer Ther; 2017 Aug; 17(8):717-723. PubMed ID: 28621163
[TBL] [Abstract][Full Text] [Related]
8. Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial.
Wiemer EAC; Wozniak A; Burger H; Smid M; Floris G; Nzokirantevye A; Sciot R; Sleijfer S; Schöffski P
Eur J Cancer; 2017 Apr; 75():33-40. PubMed ID: 28214655
[TBL] [Abstract][Full Text] [Related]
9. FDA Approves Eribulin for Advanced Liposarcoma.
Landhuis E
Cancer Discov; 2016 Mar; 6(3):OF1. PubMed ID: 26842649
[No Abstract] [Full Text] [Related]
10. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes.
Schöffski P; Ray-Coquard IL; Cioffi A; Bui NB; Bauer S; Hartmann JT; Krarup-Hansen A; Grünwald V; Sciot R; Dumez H; Blay JY; Le Cesne A; Wanders J; Hayward C; Marreaud S; Ouali M; Hohenberger P;
Lancet Oncol; 2011 Oct; 12(11):1045-52. PubMed ID: 21937277
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma.
Kawai A; Araki N; Naito Y; Ozaki T; Sugiura H; Yazawa Y; Morioka H; Matsumine A; Saito K; Asami S; Isu K
Jpn J Clin Oncol; 2017 Feb; 47(2):137-144. PubMed ID: 28173193
[TBL] [Abstract][Full Text] [Related]
12. Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine.
Demetri GD; Schöffski P; Grignani G; Blay JY; Maki RG; Van Tine BA; Alcindor T; Jones RL; D'Adamo DR; Guo M; Chawla S
J Clin Oncol; 2017 Oct; 35(30):3433-3439. PubMed ID: 28854066
[TBL] [Abstract][Full Text] [Related]
13. Delayed use of eribulin in a heavily pretreated liposarcoma patient, previously misdiagnosed as leiomyosarcoma.
Martorana F; Vigneri P; Manzella L; Tirrò E; Soto Parra HJ
Future Oncol; 2020 Jan; 16(1s):9-13. PubMed ID: 31916463
[TBL] [Abstract][Full Text] [Related]
14. FDA Approval Summary: Eribulin for Patients with Unresectable or Metastatic Liposarcoma Who Have Received a Prior Anthracycline-Containing Regimen.
Osgood CL; Chuk MK; Theoret MR; Huang L; He K; Her L; Keegan P; Pazdur R
Clin Cancer Res; 2017 Nov; 23(21):6384-6389. PubMed ID: 28242632
[TBL] [Abstract][Full Text] [Related]
15. Experience with eribulin in pretreated patients with advanced liposarcoma: a case series.
Paioli A; Setola E; Palmerini E; Cesari M; Longhi A
Future Oncol; 2020 Jan; 16(1s):25-32. PubMed ID: 31858818
[TBL] [Abstract][Full Text] [Related]
16. Interim results of a real-world observational study of eribulin in soft tissue sarcoma including rare subtypes.
Kobayashi E; Naito Y; Asano N; Maejima A; Endo M; Takahashi S; Megumi Y; Kawai A
Jpn J Clin Oncol; 2019 Oct; 49(10):938-946. PubMed ID: 31365116
[TBL] [Abstract][Full Text] [Related]
17. Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study.
Blay JY; Schöffski P; Bauer S; Krarup-Hansen A; Benson C; D'Adamo DR; Jia Y; Maki RG
Br J Cancer; 2019 May; 120(11):1026-1032. PubMed ID: 31065111
[TBL] [Abstract][Full Text] [Related]
18. Pharmacotherapy for liposarcoma: current state of the art and emerging systemic treatments.
Suarez-Kelly LP; Baldi GG; Gronchi A
Expert Opin Pharmacother; 2019 Aug; 20(12):1503-1515. PubMed ID: 31136210
[No Abstract] [Full Text] [Related]
19. Dedifferentiated liposarcoma: when eribulin can make the difference.
Sbrana A; Paolieri F; Bloise F; Manacorda S; Nuzzo A; Sammarco E; Galli L; Falcone A
Future Oncol; 2020 Jan; 16(1s):21-24. PubMed ID: 31872768
[TBL] [Abstract][Full Text] [Related]
20. Complete Response to Eribulin in a Patient with Unresectable Liposarcoma: A Case Report and Implications of New Biomarkers.
Nakamura H; Takada K; Emori M; Hayasaka N; Sugita S
Intern Med; 2022 Dec; 61(23):3617-3621. PubMed ID: 35527027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
